The results suggest that the benefits of first line TKIs for NSCLC with EGFR mutation are possibly better than those of platinum-based regimens in patients without VM, but TKIs seem to be no superior to chemotherapy in patients with VM. Here, EGFR is linked to non-small cell lung carcinoma.